Meeting
2015 ASCO Annual Meeting
Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.
Authors
Laura Vidal Boixader
Hospital Clinic Barcelona, Barcelona, Spain
Laura Vidal Boixader , Lydia Gaba , Iván Victoria , Merce Brunet , Pilar Paredes , Elvira Buxo , Teresa Vilella , Gisela Riu , Marc Cortal , Mariana Gomez-Ferreria , Jose Alfon , Carles Domenech , Pedro Gascon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT02201823
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2585)
DOI
10.1200/jco.2015.33.15_suppl.2585
Abstract #
2585
Poster Bd #
301
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
First Author: Sun Young Rha
Poster
2018 ASCO Annual Meeting
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
First Author: Mark N. Stein
Poster
2017 ASCO Annual Meeting
Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
First Author: Andres Poveda
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit